Health

GSK to sell two travel vaccines to Danish biotech firm

GSK to sell two travel vaccines to Danish biotech firm 45
GSK to sell two travel vaccines to Danish biotech firm 55

FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Photo

(Reuters) – GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).

The sale of anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, by the British drugmaker includes milestone payments of up to 495 million euros.

Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur

Our Standards:The Thomson Reuters Trust Principles.

Related posts

Coronavirus UK: How to slow the spread of the virus and reduce the impact on the NHS

news

China virus cases spike, 17 new infections reported

news

Congo to begin Ebola vaccinations on Monday

news

Leave a Comment